Disc Medicine reports $791M cash; bitopertin NDA under priority review with CNPV

Disc Medicine, Inc.

Preliminary unaudited cash, equivalents and securities ~$791M as of Dec 31, 2025; runway into 2029.
Bitopertin NDA for EPP accepted under accelerated approval; CNPV expected to accelerate FDA review to 1-2 months.
Key 2026 milestones: updated Phase 2 data for DISC-0974 (MF anemia) and DISC-3405 (PV/SCD) in H2.
Preparation for US launch of bitopertin if approved; commercial team and infrastructure build-out completed.
Phase 2 study of DISC-0974 in anemia and inflammatory bowel disease to be initiated in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.